Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $15.95
Latest analyst grade actions
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 73.24 | Oscillator | Sell |
| Stochastic %K (14, 3, 3) | 96.51 | Oscillator | Sell |
| Williams %R (14) | -1.59 | Oscillator | Sell |
| MACD (12, 26, 9) | 0.26 (Hist 0.17) | Oscillator | Strong Buy |
| Average Directional Index (14) | 12.44 (+DI 29.6 / -DI 23.7) | Trend | Neutral |
| EMA 20 | 15.02 | MA | Strong Buy |
| SMA 20 | 14.77 | MA | Strong Buy |
| EMA 50 | 14.76 | MA | Strong Buy |
| SMA 50 | 14.85 | MA | Strong Buy |
| SMA 200 | 14.67 | MA | Strong Buy |
TTM vs. 5-year historical average (annual ratios)
| Metric | ALPMY | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 12.3x | 60.1x · sector 20.7x | Discount |
| Forward P/E (FY27E) | 0.1x | EPS est. 207.73 | Discount |
| Price / Book | 2.3x | 2.1x | In line |
| Price / Sales | 2.0x | 2.0x | In line |
| EV / EBITDA | 7.2x | 13.1x | Discount |
| Return on equity | 20.4% | — | Top tier |
| Gross margin | 74.7% | 79.0% | In line |
| Debt / Equity | 0.30 | 0.31 | Conservative |
| Piotroski / Altman Z | 8/9 | Z 3.13 | Safe zone |
Discounted cash flow model
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
Stock news · updated daily
Here is how Elevance Health (ELV) and Astellas Pharma Inc. (ALPMY) have performed compared to their sector so far this year.
Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) and Bristol Myers Squibb (NYSE: BMY - Get Free Report) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk. Profitability This table compares Astellas Pharma
Shares of Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) gapped down before the market opened on Monday. The stock had previously closed at $14.20, but opened at $13.48. Astellas Pharma shares last traded at $13.5405, with a volume of 1,081 shares. Wall Street Analyst Weigh In Separately, Zacks Research cut Astellas Pharma from a
Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the recipient of a significant growth in short interest during the month of September. As of September 30th, there was short interest totaling 155,427 shares, a growth of 519.9% from the September 15th total of 25,074 shares. Approximately 0.0% of the company's stock are short sold.
Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.
Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) and Kyowa Kirin (OTCMKTS:KYKOF - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, profitability, risk and valuation. Valuation and Earnings This table compares Astellas Pharma
ASEKY, ALPMY and ATS have been added to the Zacks Rank #5 (Strong Sell) List on August 19, 2026.
The portfolio outperformed the MSCI EAFE benchmark in the second quarter of 2026. Contributors include Infineon Technologies, Tokyo Electron and Recruit Holdings. Detractors include Murata Manufacturing, SoftBank Group and Astellas Pharma.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | 0.34 | 0.50 | Beat 48.7% | $4.05B |
| Apr 27, 2026 | 0.19 | 0.15 | Miss -21.6% | $3.37B |
| Feb 4, 2026 | 0.29 | 0.36 | Beat 24.8% | $3.64B |
| Oct 30, 2025 | 0.20 | 0.30 | Beat 50.5% | $3.56B |
| Jul 30, 2025 | 0.14 | 0.25 | Beat 87.3% | $3.36B |
| Apr 25, 2025 | 0.15 | 0.27 | Beat 84.3% | $3.16B |
SEC EDGAR filings · last 12 months
Proxy statement (DEF 14A) disclosures